Clinical trial
Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or…
NCT00098618 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00098618 |
|---|---|
| Title | Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer |
| Official title | A Phase 2 Study Of BAY 43-9006 In Combination With Interferon Alfa-2b In Metastatic Renal Cell Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Clear Cell Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer |
| Intervention type | Biological, Drug, Other |
| Interventions | sorafenib tosylate, recombinant interferon alfa, laboratory biomarker analysis |
| Enrollment | 40 |
| Start date | Oct 1, 2004 |
| Primary completion | Jan 1, 2006 |
| First posted | Dec 8, 2004 |
| Last update posted | Jul 2, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: